Website & contact details
- Website
Nucleome Therapeutics Limited
- Incorporated
- 17 July 2019 (7 years)
- Industry
- Research and experimental development on biotechnology (72110)
- Directors
- Mark BodmerJohn Davis
- Controlled by
- Accounts type
- Small
- Region
- South East
- Address
- Nucleome Therapeutics LimitedInventaBotley RoadOxfordOX2 0HA
Filing status
- Accounts due
- 30 September 2027
- Last accounts
- 31 December 2025
- Conf. stmt due
- 30 August 2027
- Last conf. stmt
- 16 August 2026
Officers 8 active
Officer details are public data from the Companies House register.
Russian
Born June 1992 (34)
Bodmer, Mark
Director · Appointed 24 July 2024
British
Born June 1957 (69)
Davis, John
Director · Appointed 15 February 2024
American
Born March 1962 (64)
Greig, Russell George, Dr
Director · Appointed 6 September 2023
American,British
Born June 1952 (74)
Anninga, Bauke, Dr
Director · Appointed 21 October 2022
Dutch
Born December 1986 (39)
American
Born June 1975 (51)
Director · Appointed 30 November 2020
British
Born April 1971 (55)
Hughes, James Raymond
Director · Appointed 17 July 2019
British,Irish
Born September 1968 (58)
Officer history (5 former)
4 December 2025
4 December 2025
4 December 2025
26 July 2024
Resigned Boyd, Phil as Secretary
24 July 2024
Appointed Bodmer, Mark as Director
19 April 2024
Resigned Jeziorska, Danuta Mariola, Dr as Director
15 February 2024
Appointed Davis, John as Director
6 September 2023
Appointed Greig, Russell George, Dr as Director
2 March 2023
21 October 2022
Appointed Anninga, Bauke, Dr as Director
21 October 2022
Appointed Boyd, Phil as Secretary
21 October 2022
21 October 2022
30 November 2020
16 October 2020
2 August 2019
2 August 2019
Appointed Jeziorska, Danuta Mariola, Dr as Director
17 July 2019
Appointed Hughes, James Raymond as Director
Ownership 1 active
People and entities with significant control, from the Companies House PSC register
Corporate entity · Notified 2 August 2019
Holds 25–50% of voting rights
Corporate
Reg. no. 09093331
Former controllers (1)
29 July 2019
Ceased James Raymond Hughes — Owns 75–100% of shares
Group structure 18 shown
Ownership group derived from the Companies House PSC register
Acionna Therapeutics Ltd Owns 50–75% of shares
Animal Dynamics Limited Owns 50–75% of shares
Archangel Lightworks Ltd Owns 25–50% of shares
Ascension Earth Resources Ltd Owns 25–50% of shares
Caudal Energy Limited Owns 25–50% of shares
Caudal Morlais Limited Owns 75–100% of shares
Circadian Therapeutics Limited Owns 75–100% of shares
Cora Biosciences Limited Owns 25–50% of shares
Credo Therapies Ltd Owns 50–75% of shares
Densix Limited Owns 25–50% of shares
Dyna Therapeutics Limited Owns 50–75% of shares
Eligentis Limited Owns 25–50% of shares
Evox Therapeutics Limited Owns 25–50% of shares
Fluorok Limited Owns 25–50% of shares
Nucleome Therapeutics Limited This company Holds 25–50% of voting rights
Financials
Figures from 2020 accounts. Newer accounts, made up to 31 December 2025, are filed but not read yet. See them on Companies House
- Net Assets
- £4,659,071
- Cash
- £4,379,889
- Employees
- 4
- Debt Ratio
- 1%
- Current Ratio
- 89.1x
Balance sheet detail
| 2020 | |
|---|---|
| Fixed Assets | £203,520 |
| Current Assets | £4,506,147 |
| Cash | £4,379,889 |
| Creditors (< 1 year) | £50,596 |
| Net Current Assets | £4,455,551 |
| Net Assets | £4,659,071 |
| Shareholder Funds | £4,659,071 |
Filings
Recent filings only. See the full history on Companies House
| Date | Description | Made Up To | Pages | |
|---|---|---|---|---|
| 3 September 2026 | Confirmation statement with updates | 16 August 2026 | ||
| 28 August 2026 | Statement of capital following an allotment of shares | |||
| 13 August 2026 | Statement of capital following an allotment of shares |
Other companies in this industry
By trade and location
Need accounts figures, ownership or websites for thousands of companies? Bulk data & API →